Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 Tesla: A cross-over comparison of gadobenate dimeglumine and gadoxetic acid

Journal of Magnetic Resonance Imaging

Volumn 34, Issue 3, 2011, Pages 585-594

  Frydrychowicz, Alex ^a   Nagle, Scott K ^a,b   D'Souza, Sharon L ^a   Vigen, Karl K ^b   Reeder, Scott B ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Wisconsin Madison   (United States)

Author keywords

gadobenate dimeglumine; gadoxetic acid; hepatobiliary imaging; MR cholangiography

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOXETIC ACID;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; CONTRAST NOISE RATIO; CROSSOVER PROCEDURE; DIAGNOSTIC IMAGING; FEMALE; HEPATIC VEIN; HEPATOBILIARY SYSTEM; HUMAN; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PORTAL VEIN; PRIORITY JOURNAL; SIGNAL NOISE RATIO;

ADULT; BILIARY TRACT; CONTRAST MEDIA; CROSS-OVER STUDIES; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIGNAL-TO-NOISE RATIO; YOUNG ADULT;

EID: 80051944539     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22713     Document Type: Article

References (38)

1. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478. (Pubitemid 40139918)
2. Grazioli L, Morana G, Kirchin MA, Schneider G,. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236: 166-177. (Pubitemid 40853309)
3. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005; 237: 89-98. (Pubitemid 41346150)
4. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18: 457-467. (Pubitemid 351248177)
5. Raman SS, Leary C, Bluemke DA, et al. Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 2010; 34: 163-172.
6. Lee MS, Lee JY, Kim SH, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI. J Magn Reson Imaging 2011; 33: 149-159.
7. Dahlstrom N, Persson A, Albiin N, Smedby O, Brismar TB,. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects. Acta Radiol 2007; 48: 362-368. (Pubitemid 46633865)
8. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199: 177-183. (Pubitemid 26098637)
9. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine-a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR Am J Roentgenol 1992; 158: 887-892.
10. Schuhmann-Giampieri G,. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. Invest Radiol 1993; 28: 753-761. (Pubitemid 24081774)
11. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792.
12. Brismar TB, Dahlstrom N, Edsborg N, Persson A, Smedby O, Albiin N,. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol 2009; 50: 709-715.
13. Motosugi U, Ichikawa T, Sano K, et al. Double-dose gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol 2011; 46: 141-145.
14. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ,. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-724. (Pubitemid 41546838)
15. Winterer JT, Moske-Eick O, Markl M, Frydrychowicz A, Bley TA, Langer M,. Bilateral ce-MR angiography of the hands at 3.0 T and 1.5 T: intraindividual comparison of quantitative and qualitative image parameters in healthy volunteers. Eur Radiol 2008; 18: 658-664. (Pubitemid 351447771)
16. Stalder AF, Elverfeldt DV, Paul D, Hennig J, Markl M,. Variable echo time imaging: signal characteristics of 1-M gadobutrol contrast agent at 1.5 and 3T. Magn Reson Med 2008; 59: 113-123.
17. Cashen TA, Carr JC, Shin W, et al. Intracranial time-resolved contrast-enhanced MR angiography at 3T. AJNR Am J Neuroradiol 2006; 27: 822-829. (Pubitemid 44897730)
18. Merkle EM, Dale BM, Barboriak DP,. Gain in signal-to-noise for first-pass contrast-enhanced abdominal MR angiography at 3 Tesla over standard 1.5 Tesla: prediction with a computer model. Acad Radiol 2007; 14: 795-803. (Pubitemid 46908778)
19. Michaely HJ, Kramer H, Dietrich O, et al. Intraindividual comparison of high-spatial-resolution abdominal MR angiography at 1.5 T and 3.0 T: initial experience. Radiology 2007; 244: 907-913. (Pubitemid 47292104)
20. Nagle SN, Busse RF, Brau AC, et al. High-resolution free-breathing 3D T1 weighted hepatobiliary imaging optimized for Gd-EOB-DTPA. In: Proceedings of the 18th Annual Meeting of ISMRM, Honolulu, 2009. (abstract 2076).
21. Bashir MR, Merkle EM,. Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol 2011; 21: 291-294.
22. Pruessmann KP, Weiger M, Scheidegger MB, Boesiger P,. SENSE: sensitivity encoding for fast MRI. Magn Reson Med 1999; 42: 952-962. (Pubitemid 29521486)
23. Reeder SB, Wintersperger BJ, Dietrich O, et al. Practical approaches to the evaluation of signal-to-noise ratio performance with parallel imaging: application with cardiac imaging and a 32-channel cardiac coil. Magn Reson Med 2005; 54: 748-754. (Pubitemid 41233774)
24. Prince MR, Chenevert TL, Foo TK, Londy FJ, Ward JS, Maki JH,. Contrast-enhanced abdominal MR angiography: optimization of imaging delay time by automating the detection of contrast material arrival in the aorta. Radiology 1997; 203: 109-114. (Pubitemid 27142716)
25. Brau AC, Beatty PJ, Skare S, Bammer R,. Comparison of reconstruction accuracy and efficiency among autocalibrating data-driven parallel imaging methods. Magn Reson Med 2008; 59: 382-395. (Pubitemid 351220102)
26. Runge VM,. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J Comput Assist Tomogr 1998; 22: 643-650. (Pubitemid 28433803)
27. Constantinides CD, Atalar E, McVeigh ER,. Signal-to-noise measurements in magnitude images from NMR phased arrays. Magn Reson Med 1997; 38: 852-857. (Pubitemid 27467727)
28. Dietrich O, Raya JG, Reeder SB, Ingrisch M, Reiser MF, Schoenberg SO,. Influence of multichannel combination, parallel imaging and other reconstruction techniques on MRI noise characteristics. Magn Reson Imaging 2008; 26: 754-762.
29. Manfredi R, Maresca G, Baron RL, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 1999; 9: 704-710. (Pubitemid 29211165)
30. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology 2000; 215: 727-736. (Pubitemid 30346007)
31. Schima W, Petersein J, Hahn PF, Harisinghani M, Halpern E, Saini S,. Contrast-enhanced MR imaging of the liver: comparison between Gd-BOPTA and Mangafodipir. J Magn Reson Imaging 1997; 7: 130-135. (Pubitemid 28365648)
32. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D,. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008; 18: 1577-1586.
33. Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 2008; 43: 202-210. (Pubitemid 351643147)
34. Kim YK, Lee JM, Kim CS,. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 2004; 14: 5-13. (Pubitemid 38181049)
35. Marin D, Di Martino M, Guerrisi A, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 2009; 251: 85-95.
36. Asbach P, Warmuth C, Stemmer A, et al. High spatial resolution T1-weighted MR imaging of liver and biliary tract during uptake phase of a hepatocyte-specific contrast medium. Invest Radiol 2008; 43: 809-815.
37. Jedynak AR, Kelcz F, Frydrychowicz A, Nagle SN, Reeder SB,. Clinical experience with gadoxetate-enhanced T1 weighted hepatobiliary imaging in primary sclerosing cholangitis. In: Proceedings of the 18th Annual Meeting of ISMRM, Stockholm, Sweden, 2010. (abstract 2620).
38. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE,. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999; 290: 153-157. (Pubitemid 29302315)